Skip to main content

RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform

--News Direct--

RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an overview of the lead candidate product RenovoGem that he has presented to the Congress, before going on to explain where the product is in its development cycle. He says the product has met with "a lot of enthusiasm" so far and reveals his hopes of getting early approval from the FDA "next year or early in 2025."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/renovorx-encountering-a-lot-of-enthusiasm-for-innovative-cancer-platform-744883148

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.